President and Chief Operating Officer
United States of America
Ms. McCourt joined our board in January 2017. Ms. McCourt brings to the board more than two decades of wide-ranging leadership experience at several of the world's most respected and innovative biopharmaceutical companies. Since April 2017, Ms. McCourt has served as the President and Chief Operating Officer of Axovant Sciences, Inc. (NYSE:AXON). Prior to joining Axovant Sciences, Ms. McCourt served as Chief Operating Officer of Medivation, Inc. from February 2016 until its acquisition by Pfizer Inc. (NYSE:PFE). Prior to Medivation, Ms. McCourt served as Vice President of U.S. Commercial Operations at Amgen Inc. (NASDAQ:AMGN), one of the world's leading independent biotechnology companies. Prior to that, she also served as Vice President and General Manager of Amgen's Bone Health & Primary Care Business Unit. Before joining Amgen, Ms. McCourt held numerous positions of increasing responsibility over a twelve-year career at AstraZeneca (NYSE:AZN) in the U.S. and Canada. There, she ultimately achieved the title of Chief Operating Officer of AstraZeneca U.S. where she was responsible for all U.S. commercial functions, including medical affairs, business development, finance, human resources, legal, operations, and corporate affairs. Ms. McCourt currently serves on the board of CytomX Therapeutics, Inc. (NASDAQ:CTMX). Ms. McCourt holds a B.S. degree in Biology from Lafayette College.